Nanoparticle Platform Shows Progress in Flu Vaccine Development
Post Date: March 25, 2022 | Publish Date: March 22, 2022
A nanoparticle-based platform for vaccine development discovered by experts at Cincinnati Children’s and licensed to the company Blue Water Vaccines Inc. shows signs, in mice, of success against HA1 influenza.
Ming Tan, PhD, Division of Infectious Diseases, served as principal investigator of the study, published in the journal Nano Research.
The paper describes the performance of the team’s S60-HA1 pseudovirus nanoparticles (PVNPs).
“The PVNPs are highly immunogenic, eliciting high titers of HA1-specific antibodies in mice and the mouse sera strongly inhibited hemagglutinations of homologous and heterologous influenza virus HA proteins,” the co-authors state.
Blue Water Vaccines is using the norovirus shell and protrusion (S&P) platform to develop BWV-301, a vaccine for gastroenteritis caused by norovirus or rotavirus infection.
“This latest publication highlights the versatility of the S&P platform beyond norovirus/rotavirus application and supports BWV’s exploration of utilizing the novel S&P platform to develop vaccine candidates against H1, H3, and Flu B infections,” the company states.
Read the Blue Water Vaccines announcement
Nanoparticle Technology Licensed to Vaccine Development Firm
Read more about P-particle research at Cincinnati Children’s
Download PDF of Research Horizons article, Winter 2014
|Original title:||Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity|
|Published in:||Nano Research|
|Publish date:||March 22, 2022|